NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: CURIS · data 2026-10-31
Curis Lifesciences Limited
In plain words
Price: 23.3% below its 52-week high of ₹234.75.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹61 cr |
| Net profit (last 12 months) | ₹7 cr |
| Sales growth, 3 years (yearly) | 19.6% |
| Profit growth, 3 years (yearly) | 78.0% |
At a glance
P/E 21.2, P/B 3.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 21.7%, ROCE 26.6%, operating margin 17.2%: how much profit it earns on the money it uses.
Debt/equity 0.46, Profit growth 78.0% and sales growth 19.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (21.7%).
- Profit grew 78.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Curis Lifesciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.46.
What is Curis Lifesciences Limited's P/E ratio?
About 21.2, based on the last 12 months' earnings and a price of ₹180 (data 2026-10-31).
What is the 52-week high and low of Curis Lifesciences Limited?
The 52-week high is ₹234.75 and the 52-week low is ₹83.6.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Curis Lifesciences Limited | ₹180 | ₹146 cr | 21.2 | 3.1 | 21.7% | 26.6% | 0.46 | +23.2% |
| Medico Remedies Ltd. | ₹18.61 | ₹155 cr | 11.2 | — | 19% | 20.4% | 0.26 | -61.3% |
| Quest Laboratories Ltd. | ₹82 | ₹134 cr | 9 | 1.4 | 16.7% | 19.3% | 0.08 | -6.8% |
| Bal Pharma Limited | ₹81.85 | ₹129 cr | 18.1 | — | 7.9% | 19.2% | 2.03 | -2.4% |
| Krebs Biochemicals & Industries Ltd. | ₹56.6 | ₹126 cr | — | — | — | -17.3% | — | -18.6% |
| Sotac Pharmaceuticals Limited | ₹111.65 | ₹123 cr | 21.4 | 2.1 | 10.3% | 17.4% | 0.64 | -6.1% |
Compare CURIS with MEDICO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CURIS in NSE Scanner →